loading
Precedente Chiudi:
$14.62
Aprire:
$14.71
Volume 24 ore:
224.88K
Relative Volume:
0.34
Capitalizzazione di mercato:
$1.34B
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-3.6086
EPS:
-3.96
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
-9.07%
1M Prestazione:
-15.50%
6M Prestazione:
-16.82%
1 anno Prestazione:
+3.84%
Intervallo 1D:
Value
$14.18
$14.71
Intervallo di 1 settimana:
Value
$14.18
$16.05
Portata 52W:
Value
$13.49
$20.31

Arcus Biosciences Inc Stock (RCUS) Company Profile

Name
Nome
Arcus Biosciences Inc
Name
Telefono
(510) 694-6200
Name
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Name
Dipendente
577
Name
Cinguettio
@arcusbio
Name
Prossima data di guadagno
2024-12-06
Name
Ultimi documenti SEC
Name
RCUS's Discussions on Twitter

Confronta RCUS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
RCUS 14.32 1.34B 247.00M -249.00M -267.00M -3.96
VRTX 446.95 115.74B 10.63B -479.80M -1.35B 13.33
REGN 742.11 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 588.63 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 250.00 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.98 24.49B 3.30B -501.07M 1.03B 11.54

Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-10-21 Iniziato H.C. Wainwright Neutral
2024-10-08 Iniziato Wells Fargo Overweight
2022-11-18 Iniziato BofA Securities Neutral
2022-10-11 Iniziato Morgan Stanley Overweight
2021-10-15 Ripresa BTIG Research Buy
2020-11-24 Iniziato Berenberg Buy
2020-11-23 Iniziato Evercore ISI Outperform
2020-04-03 Iniziato Cantor Fitzgerald Overweight
2020-03-04 Iniziato Barclays Overweight
2019-11-12 Iniziato SunTrust Buy
2019-09-27 Iniziato Mizuho Buy
2019-05-24 Ripresa Citigroup Buy
2018-10-09 Iniziato Wedbush Outperform
2018-04-09 Iniziato Citigroup Buy
2018-04-09 Iniziato Goldman Neutral
2018-04-09 Iniziato Leerink Partners Outperform
Mostra tutto

Arcus Biosciences Inc Borsa (RCUS) Ultime notizie

pulisher
05:57 AM

Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking - Simply Wall St

05:57 AM
pulisher
Nov 20, 2024

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Arcus Biosciences to Present at Evercore and Citi Healthcare Conferences in December | RCUS Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 13, 2024

Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Bolsters Stake in Arcus Biosciences Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Arcus Biosciences Awards Key Equity Grants to New Hires at $17.85 Per Share | RCUS Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

GSA Capital Partners LLP Raises Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

FY2024 Earnings Forecast for RCUS Issued By HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report - Yahoo Finance

Nov 09, 2024
pulisher
Nov 07, 2024

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Arcus Biosciences (NYSE:RCUS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: S - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $33.67 - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of “Buy” from Analysts - Defense World

Nov 07, 2024
pulisher
Nov 06, 2024

Arcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024
pulisher
Nov 06, 2024

Arcus Biosciences Surges: 34% Cancer Trial Success, AstraZeneca Deal Boosts Q3 | RCUS Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Arcus Biosciences (NYSE:RCUS) Receives "Neutral" Rating from HC Wainwright - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

Arcus up 4% following Merck Welireg kidney cancer data - MSN

Nov 06, 2024
pulisher
Nov 05, 2024

Arcus says Gilead-partnered cancer therapy cut death risk by 36% - Seeking Alpha

Nov 05, 2024
pulisher
Nov 05, 2024

Arcus reports improved survival with cancer drug combo - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Arcus Biosciences (RCUS) Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10 - StreetInsider.com

Nov 05, 2024
pulisher
Nov 05, 2024

Arcus Bio's Cancer Drug Combo Cuts Death Risk by 36%, Doubles Survival Time in Lung Cancer Trial | RCUS Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Allspring Global Investments Holdings LLC - Defense World

Nov 04, 2024
pulisher
Nov 03, 2024

(RCUS) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 03, 2024
pulisher
Oct 31, 2024

This Arcus Biosciences Insider Reduced Their Stake By 27% - Simply Wall St

Oct 31, 2024
pulisher
Oct 31, 2024

Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for - MSN

Oct 31, 2024
pulisher
Oct 30, 2024

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting - StockTitan

Oct 30, 2024
pulisher
Oct 30, 2024

Arcus Biosciences (RCUS) Set to Announce Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Arcus Biosciences: Advancing On Several Fronts (NYSE:RCUS) - Seeking Alpha

Oct 29, 2024
pulisher
Oct 25, 2024

Arcus Biosciences (NYSE:RCUS) Trading Down 5.3%Should You Sell? - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Arcus Biosciences (NYSE:RCUS) Price Target Raised to $29.00 at Barclays - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Arcus Biosciences' SWOT analysis: stock outlook hinges on clinical trials - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Arcus Begins Differentiating Its HIF-2a inhibitor Versus Merck’s Welireg - Scrip

Oct 24, 2024
pulisher
Oct 24, 2024

Arcus Biosciences Announces New Employment Inducement Grants - StockTitan

Oct 24, 2024
pulisher
Oct 24, 2024

Health Care Down Amid Mixed Drug Developments -- Health Care Roundup - Marketscreener.com

Oct 24, 2024
pulisher
Oct 24, 2024

Citi raises Arcus Biosciences target to $46, maintains buy By Investing.com - Investing.com Canada

Oct 24, 2024
pulisher
Oct 24, 2024

Arcus Biosciences (RCUS) PT Raised to $46 at Citi - StreetInsider.com

Oct 24, 2024
pulisher
Oct 24, 2024

Neutral stance on Arcus Biosciences maintained by BofA - Investing.com Canada

Oct 24, 2024
pulisher
Oct 24, 2024

BofA Securities Reiterates Neutral Rating on Arcus Biosciences (RCUS) - StreetInsider.com

Oct 24, 2024
pulisher
Oct 24, 2024

Arcus Biosciences (NYSE:RCUS) Sees Large Volume IncreaseWhat's Next? - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Arcus Biosciences' SWOT analysis: stock outlook hinges on clinical trials By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 24, 2024

Arcus Biosciences Inc (NYSE: RCUS) Could Slash -153.89% Soon - Stocks Register

Oct 24, 2024
pulisher
Oct 24, 2024

Arcus Biosciences Shares Rise After Kidney Cancer Drug Shows Promise in Early-Stage Trial - MarketWatch

Oct 24, 2024
pulisher
Oct 24, 2024

First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer - StockTitan

Oct 24, 2024
pulisher
Oct 24, 2024

(RCUS) Technical Pivots with Risk Controls - Stock Traders Daily

Oct 24, 2024
pulisher
Oct 23, 2024

Arcus started at neutral by H.C. Wainwright, upcoming data cited - MSN

Oct 23, 2024
pulisher
Oct 23, 2024

Research Analysts Issue Forecasts for RCUS Q3 Earnings - MarketBeat

Oct 23, 2024

Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):